<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04834557</url>
  </required_header>
  <id_info>
    <org_study_id>Treating Rheumatoid Arthritis</org_study_id>
    <nct_id>NCT04834557</nct_id>
  </id_info>
  <brief_title>Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis in Egypt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the potential therapeutic effects of the cardiac&#xD;
      glycoside digoxin and the secondary bile acid ursodeoxycholic acid (UDCA) on synovial&#xD;
      inflammation and disease activity when administered as add-on treatments to the current&#xD;
      DMARDs treatments for rheumatoid arthritis patients with variant disease activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, open-labeled, controlled prospective study to evaluate the&#xD;
      potential therapeutic effects of the cardiac glycoside digoxin and the secondary bile acid&#xD;
      ursodeoxycholic acid (UDCA) on synovial inflammation and disease activity when administered&#xD;
      as add-on treatments to the current DMARDs treatments for rheumatoid arthritis patients with&#xD;
      variant disease activity. The study population will be rheumatoid arthritis patients&#xD;
      attending the Physical Medicine, Rheumatology and Rehabilitation Department at Menoufia&#xD;
      University Hospital, Menoufia, Egypt. A total of 90 rheumatoid arthritis patients who will&#xD;
      meet the inclusion criteria will be enrolled in this study. The 90 participants will be&#xD;
      divided into 30 rheumatoid arthritis patients who will receive placebo + the current DMARDs&#xD;
      treatments of rheumatoid arthritis for 24 weeks and serve as the control group, 30 rheumatoid&#xD;
      arthritis patients who will receive DMARDs + digoxin 25 mg every other day for 24 weeks and&#xD;
      the last 30 rheumatoid arthritis patients who will receive DMARDs + ursodeoxycholic acid&#xD;
      (UDCA) 500 mg/day for 24 weeks. Clinical Examinations and laboratory parameters will be&#xD;
      performed and measured at the beginning of the study, 12 weeks and 24 weeks after&#xD;
      randomization to evaluate the efficacy of digoxin and UDCA in the treatment of rheumatoid&#xD;
      arthritis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is a randomized controlled prospective study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from Baseline in Clinical Disease Activity Index (CDAI) Score</measure>
    <time_frame>Baseline, after 12 weeks, after 24 weeks</time_frame>
    <description>To evaluate the effect of the use of digoxin and UDCA as an add-on therapy in patients with rheumatoid arthritis by evaluating the change from baseline in the clinical findings as measured by Clinical Disease Activity Index (CDAI) scores. A lower CDAI score from Baseline would mean improvement in disease activity and an increase in CDAI score from Baseline would mean an increase in disease activity or a worsening in disease activity. Scores: 0.0-2.8 = Range for Remission; 2.9-10.0 = Range for Low disease activity; 10.1-22.0 Range for Moderate disease activity; 22.1-76 Range for High disease activity. Total range is from 0-100, with the high scores representing high disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in C-Reactive Protein (CRP) Values and Erythrocyte Sedimentation Rates (ESR)</measure>
    <time_frame>Baseline, after 12 weeks, after 24 weeks</time_frame>
    <description>C- reactive Protein (CRP) values and Erythrocyte Sedimentation Rate (ESR) will be made at baseline and after 12 as well as 24 weeks to determine the number of patients whose test result improved or worsened CRP value (normal range &lt;1.0 mg/dl). ESR (normal range 0-28 mm/hr) . If the value is increased, the disease activity worsened. If the value is reduced the disease activity is improved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline Measurement of IL-17A and HIF-1α at 12 and 24 weeks</measure>
    <time_frame>Baseline, after 12 weeks, after 24 weeks</time_frame>
    <description>Serum IL-17A and HIF-1α levels will be measured by means of the human enzyme-linked immunosorbent assay (ELISA) technique according to the manufacturer's protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of participants with treatment-related adverse events</measure>
    <time_frame>Baseline, after 12 weeks, after 24 weeks</time_frame>
    <description>The adverse events in each group will be observed and documented during the whole procedure to show the safety of the treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will receive Placebo with the current DMARDs treatments for rheumatoid arthritis for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Digoxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive digoxin 0.25 mg every other day + DMARDs for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ursodeoxycholic acid (UDCA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive ursodeoxycholic acid (UDCA) 500 mg/day + DMARDs for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin 0.25 mg</intervention_name>
    <description>All subjects will receive digoxin administered at 0.25 mg every other day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.</description>
    <arm_group_label>Digoxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic acid (UDCA) 500 mg</intervention_name>
    <description>All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.</description>
    <arm_group_label>Ursodeoxycholic acid (UDCA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with rheumatoid arthritis according to the ACR/EULAR 2010 criteria.&#xD;
&#xD;
          -  Having active rheumatoid arthritis disease activity (the 28-joint disease activity&#xD;
             score [DAS28] according to the CRP formula &gt; 2.6).&#xD;
&#xD;
          -  Aged between 18 and 80 years.&#xD;
&#xD;
          -  With clear consciousness and able to cooperate with this study.&#xD;
&#xD;
          -  Personal willingness and ability to comply with the study follow-up schedule and other&#xD;
             requirements of the study protocol.&#xD;
&#xD;
          -  Both male and female will be included&#xD;
&#xD;
          -  All patients receiving non-biological drugs will be also included.&#xD;
&#xD;
          -  Sign an informed consent for the clinical study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or planning to be pregnant and breast-feeding women&#xD;
&#xD;
          -  Patients suffering from any chronic diseases&#xD;
&#xD;
          -  Patients with other autoimmune diseases, such as systemic lupus erythematosus,&#xD;
             Sjogren's syndrome and mixed connective tissue disease.&#xD;
&#xD;
          -  Patients who have a diagnosis of any other inflammatory arthritis (e.g., psoriatic&#xD;
             arthritis or ankylosing spondylitis).&#xD;
&#xD;
          -  Patients with a history of, or suspected, demyelinating disease of the central nervous&#xD;
             system (e.g. multiple sclerosis or optic neuritis).&#xD;
&#xD;
          -  Patients with a current or recent history of severe, progressive, and/or uncontrolled&#xD;
             renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac,&#xD;
             neurological, or cerebral disease.&#xD;
&#xD;
          -  Patients treated with biological therapy such as TNF-α or IL-1β antagonists.&#xD;
&#xD;
          -  Patients with infectious or inflammatory diseases, endocrine disorders, any past or&#xD;
             current psychiatric or neurological diseases.&#xD;
&#xD;
          -  Patients with cardiovascular diseases such as arrhythmias and acute myocardial&#xD;
             infarction.&#xD;
&#xD;
          -  Patients with electrolyte disturbances (such as hypokalemia, hypomagnesemia, and&#xD;
             hypercalcemia) could potentially elevate the risk of digoxin toxicity.&#xD;
&#xD;
          -  Patients with clinically significant hepatic and renal dysfunction or impairment.&#xD;
&#xD;
          -  Alcohol abuse&#xD;
&#xD;
          -  Patients with evidence of viral (HBV or HCV), autoimmune hepatitis, and decompensated&#xD;
             liver disease.&#xD;
&#xD;
          -  Patients with cancer currently diagnosed or in medical history, if no recovery was&#xD;
             achieved.&#xD;
&#xD;
          -  Patients who are allergic to digoxin or Ursodeoxycholic acid (UDCA)&#xD;
&#xD;
          -  Patients who are unconscious and unable to complete the study.&#xD;
&#xD;
          -  Patients with acute inflammation of the gall bladder or the biliary tract, frequent&#xD;
             episodes of biliary colic, and impaired contractility of the gall bladder, will be&#xD;
             excluded.&#xD;
&#xD;
          -  Patients with cholestasis, primary biliary cirrhosis, or biliary obstruction will also&#xD;
             be excluded.&#xD;
&#xD;
          -  Patients who have received an organ transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nageh Ahmed El-Mahdy, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Professor of Pharmacology and Toxicology Faculty of Pharmacy, Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Medhat Ismail Abdel Hamid, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Professor of Pharmacology and Toxicology Faculty of Medicine, Al-Azhar University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dalia Salah Seif, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Associate Professor of Physical Medicine, Rheumatology and Rehabilitation Faculty of Medicine, Menoufyia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enass Yousef Osman, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Lecturer of Pharmacology and toxicology, Faculty of Pharmacy, Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariam George Tadros Bolous, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Lecturer of Clinical pharmacy, Faculty of Pharmacy, Sinai University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariam George Tadros, Master</last_name>
    <phone>+20 1285600693</phone>
    <email>mariam.tadros77@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dalia Salah, PHD</last_name>
    <phone>+20 1008312704</phone>
    <email>sdalia30@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569-81. doi: 10.1002/art.27584.</citation>
    <PMID>20872595</PMID>
  </reference>
  <reference>
    <citation>Neogi T, Aletaha D, Silman AJ, Naden RL, Felson DT, Aggarwal R, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Khanna D, Kvien TK, Laing T, Liao K, Mease P, Ménard HA, Moreland LW, Nair R, Pincus T, Ringold S, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G; American College of Rheumatology; European League Against Rheumatism. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum. 2010 Sep;62(9):2582-91. doi: 10.1002/art.27580.</citation>
    <PMID>20872596</PMID>
  </reference>
  <reference>
    <citation>Hua S, Dias TH. Hypoxia-Inducible Factor (HIF) as a Target for Novel Therapies in Rheumatoid Arthritis. Front Pharmacol. 2016 Jun 27;7:184. doi: 10.3389/fphar.2016.00184. eCollection 2016. Review.</citation>
    <PMID>27445820</PMID>
  </reference>
  <reference>
    <citation>Lee EJ, Kwon JE, Park MJ, Jung KA, Kim DS, Kim EK, Lee SH, Choi JY, Park SH, Cho ML. Ursodeoxycholic acid attenuates experimental autoimmune arthritis by targeting Th17 and inducing pAMPK and transcriptional corepressor SMILE. Immunol Lett. 2017 Aug;188:1-8. doi: 10.1016/j.imlet.2017.05.011. Epub 2017 May 21.</citation>
    <PMID>28539269</PMID>
  </reference>
  <reference>
    <citation>O'Dwyer AM, Lajczak NK, Keyes JA, Ward JB, Greene CM, Keely SJ. Ursodeoxycholic acid inhibits TNFα-induced IL-8 release from monocytes. Am J Physiol Gastrointest Liver Physiol. 2016 Aug 1;311(2):G334-41. doi: 10.1152/ajpgi.00406.2015. Epub 2016 Jun 23.</citation>
    <PMID>27340129</PMID>
  </reference>
  <reference>
    <citation>Saeed H, Mateen S, Moin S, Khan AQ, Owais M. Cardiac glycoside digoxin ameliorates pro-inflammatory cytokines in PBMCs of rheumatoid arthritis patients in vitro. Int Immunopharmacol. 2020 Feb 24;82:106331. doi: 10.1016/j.intimp.2020.106331. [Epub ahead of print]</citation>
    <PMID>32106058</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Mariam George Tadros Bolous</investigator_full_name>
    <investigator_title>Assistant Lecturer of Clinical pharmacy, Faculty of Pharmacy, Sinai University</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Digoxin</keyword>
  <keyword>Ursodeoxycholic acid</keyword>
  <keyword>Synovial inflammation</keyword>
  <keyword>leukocyte infiltration</keyword>
  <keyword>Autoimmune diseases</keyword>
  <keyword>Th17 and Treg cells</keyword>
  <keyword>Synovial hypoxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

